ZG005 not checked
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
FollowEvery change as it happens, and a Monday email
Trials
10 active
15 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Recommended Phase 2 Dose (RP2D) of ZG005(20 mg/kg), intravenous infusion, once every 3 weeks.”In the company’s words, NCT06927687 on ClinicalTrials.gov
- Tested for
- Advanced Solid Tumor (3 trials), Hepatocellular Carcinoma, Neuroendocrine Carcinomas (NEC), Biliary Tract Carcinoma, Lymphoma, Non-small Cell Lung Cancer, Cervical Cancer, Small Cell Lung Cancer and 1 more
- Main trialPhase 3
- “The purpose of the study is to evaluate the efficacy of ZG005 combined with bevacizumab compared with sintilimab combined with bevacizumab in the first-line treatment of participants with advanced HCC”In the company’s words, NCT07813572 on ClinicalTrials.gov
Other drugs for Advanced Solid Tumor
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up10
- Apr 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Apr 2027Phase 1/2 trial completes · ClinicalTrials.gov
- May 2027Phase 2 trial completes · ClinicalTrials.gov
- May 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Aug 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Sep 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Oct 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- Sep 2031Phase 3 trial completes · ClinicalTrials.gov
- Oct 2031Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 16 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07813572
Trials15
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Sep 2031 | ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular | |
| Phase 3Not yet recruiting | Oct 2031 | ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma | |
| Phase 2Active, not recruiting | May 2027 | Study of ZG005 in Patients With Advanced Solid Tumors | |
| Phase 2Recruiting | Dec 2027 | Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma | |
| Phase 1/2Recruiting | Apr 2027 | Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma | |
| Phase 1/2Recruiting | Apr 2027 | Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer | |
| Phase 1/2Recruiting | May 2027 | Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors | |
| Phase 1/2Recruiting | Aug 2027 | Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer | |
| Phase 1/2Recruiting | Sep 2027 | ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | |
| Phase 1/2Not yet recruiting | Oct 2027 | Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors | |
| Phase 2Unknown | Sep 2026 | Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma | |
| Phase 1/2Unknown | Mar 2026 | A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor | |
| Phase 1/2Unknown | May 2026 | Study of ZG005 in Combination With Paclitaxel+Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma | |
| Phase 1/2Completed | 22 Jul 2026 | A Study of ZG005 in Patients With Advanced Solid Tumors | |
| Phase 1/2Unknown | Jul 2026 | Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026